Dermatology Doctors in Palm Harbor, FL Accepting Medicare

9 Dermatology doctors found. Showing 1 - 9

Dr. Roger William Altman, M.D. Dermatology - MOHS-Micrographic Surgery Medicare: Medicare Enrolled Practice Location: 32615 Us Highway 19 N, Suite 1, Palm Harbor, FL 34684 Phone: 727-785-7667    Fax: 727-787-4543

Robert Patrick Albergo, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4132 Woodlands Parkway, Palm Harbor, FL 34685 Phone: 727-786-5100    Fax: 727-789-8344

John C Mavropoulos, M.D., M.P.H., PH.D. Dermatology - MOHS-Micrographic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4197 Woodlands Pkwy, Palm Harbor, FL 34685 Phone: 727-786-3810    Fax: 727-786-3855

Dr. Stephen James Lockwood, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4197 Woodlands Pkwy, Palm Harbor, FL 34685 Phone: 727-786-3810    Fax: 727-786-3855

Dr. Linda J Lokys, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1885 Lago Vista Blvd, Palm Harbor, FL 34685 Phone: 727-786-9732    Fax: 727-786-9732

Dr. Amy Simon Ross, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4197 Woodlands Pkwy, Palm Harbor, FL 34685 Phone: 727-786-3810    Fax: 727-786-3855

Sultan Mirza, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 32615 Us Highway 19 N Ste 1, Palm Harbor, FL 34684 Phone: 813-321-1786    Fax: 813-321-1787

Viba B Malaiyandi, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4197 Woodlands Pkwy, Palm Harbor, FL 34685 Phone: 727-786-3810    Fax: 727-786-3855

Nicholas Bradford Castner, MD Dermatology - MOHS-Micrographic Surgery Medicare: Medicare Enrolled Practice Location: 4197 Woodlands Pkwy, Palm Harbor, FL 34685 Phone: 727-786-3810    Fax: 727-786-3855

News Archive

Medicago and PATH partner on development of broad coverage influenza vaccine

Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.

Financial contracts to care for sick or aging relatives adding legal twist to family health care

Financial contracts to care for sick or aging relatives - nearly unthinkable just a decade ago - are drawing new interest as everyday Americans wrestle with the time and expense of providing long-term health care, a University of Illinois legal expert says.

Developing imaging techniques for early detection of eye and brain diseases

The eyes may be the window to the soul, but to scientists, they are also the window to the brain. In particular, the retina, a delicate light-sensing neural network with specialized cells at the back of the eyeball, is linked directly to the brain via the optic nerve and is considered by some to be part of the brain itself.

Lannett announces launch of Fluphenazine HCl Tablets

Lannett Company, Inc., a manufacturer of generic pharmaceuticals, today announced that it has commenced shipping Fluphenazine HCl Tablets USP, the generic equivalent of Prolixin®, in 1 mg, 2.5 mg, 5 mg and 10 mg dosages. For the 12 months ended September 2010, Fluphenazine HCl Tablets USP, 1 mg, 2.5 mg, 5 mg, & 10 mg had U.S. sales of approximately $28 million at Average Wholesale Price.

Study: 90% of patients have detectable antibodies up to 7 months post contracting COVID-19

A new study led by Marc Veldhoen, principal investigator at Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal) with an interdisciplinary team of clinicians and researchers from Faculdade de Medicina da Universidade de Lisboa (FMUL) and Centro Hospitalar Lisboa Norte (CHLN) and collaborators at Instituto Português do Sangue e Transplantação (IPST), shows that 90% of subjects have detectable antibodies 40 days up to 7 months post contracting COVID-19.

Read more Medical News

› Verified 5 days ago